Posted by Clinical Lab Products | Apr 22, 2010 | Cancer, Miscellaneous |
Clarient Inc has announced that data from a new study suggest that the Clarient Insight Dx Pulmotax assay may effectively predict which lung cancer patients will respond favorably to chemotherapy.
Read MorePosted by Clinical Lab Products | Apr 21, 2010 | Cancer, Miscellaneous |
The first lung cancer clinical trial to guide targeted therapies to patients based on molecular signatures in tumor biopsies is a step toward personalized care and more effective, efficient clinical trials for new drugs, study leaders reported.
Read MorePosted by Clinical Lab Products | Feb 12, 2010 | Cancer, Miscellaneous |
Clarient Inc, a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, has announced the commercial launch of a new lung cancer test, Clarient Insight Dx Pulmotype.
Read MorePosted by Clinical Lab Products | Dec 15, 2009 | Cancer, Lung Cancer, Molecular Diagnostics |
Clarient Inc, a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, and BioView Ltd jointly announced that they will collaborate on studies to validate the clinical utility of a non-invasive test for the early detection of non-small cell lung cancer.
Read MorePosted by Clinical Lab Products | Aug 28, 2009 | Cancer, Miscellaneous |
Abbott announced that it has entered into an agreement with Pfizer Inc to develop a molecular diagnostic test intended to screen non-small cell lung cancer (NSCLC) tumors for the presence of gene rearrangements.
Read More